RIGL
RIGL
US7665597024
Rigel Pharmaceuticals, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 294.282.000 179.278.000
64.1%
Cost of Revenue 19.621.000 18.647.000
5.2%
Gross Profit 274.661.000 160.631.000
71.0%
149.195.000 136.439.000
9.3%
Operating Income 125.466.000 24.192.000
418.6%
Pretax Income 121.827.000 18.366.000
563.3%
Net Income Common Stockholders 367.024.000 17.485.000
1999.1%
-- --
--
-- --
--
ende